New York City
Saturday, June 15, 2024
“THE CEO PUBLICATION owns both and websites"


COVID vaccine candidate appears to be a safe trial on human being continues

The COVID vaccine candidate appears to be safe in human trials.

July 15, 2020: A candidate vaccine against the COVID-19 has entered human trials and, many humans are involved in the early stage of vaccine testing. The concern with the coronavirus attack is, it will weaker your immune system so, the vaccine designed is to boost the immune system of the infected body. The vaccine deployed by the Federal Government and Moderna Inc. is safe has improved the immune in the tested body as per the report released on Tuesday. The officials also say it is too early to conclude the initial stage of testing.

Moderna’s, chief medical officer Dr. Tal Zaks said the vaccine designed mRNA-1273 is safe and effective and, it is a  good result in the testing stage of the medicine. The clinical trial led by Dr. Anthony Fauci’s, Vaccine Research Center at the National Institutes of Health. March 16, the Chinese scientist revealed the genetic sequence and, right after two months, we have an antibody tested for a group of humans here in the United States.

A total of 48 participants divided into three different groups and injected the antibody in three different quantities. One group with a high dose, medium dose, and low dose respectively. It was injected twice in a month to the participants. We are unsure how much antibody is required to fight against the virus and what is the composition of the virus in a different body. However, the mRNA-1273 has helped to increase the immune in the respective dosage. It is seen that the result was similar to the patients who recovered from the COVID-19. The vaccine was able to generate the antibody to neutralize the virus in the early trials.

“It looks like their vaccine was able to induce virus-neutralizing antibody, which is positive,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston. “But it’s hard to know if the level of virus-neutralizing antibody will be sufficient to induce protective immunity, or if it compares favorably with other (vaccine) candidates”.

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, notifications only about new products, updates.

Most Popular

Receive the latest news

Request for online magazine

Join Us

Advertise with us

meteroid vecrtor
Receive the latest news

Contact Us